Fast, Actionable, 32 Gene Panel

Small But Mighty: OncoCore Yields Fast, Actionable Insights into Cancer Genetics

Choosing the right gene panel for cancer diagnostics is crucial for optimal patient care. While large panels that screen hundreds of genes provide comprehensive data, they come with high costs and prolonged turnaround times, often yielding ambiguous results. Smaller panels may miss essential genes critical for diagnosis or treatment planning. Striking a balance between gene inclusivity and data manageability is key to providing clinicians with meaningful, actionable information to enhance patient care. That’s why we developed OncoCore, an NGS panel designed to detect clinically significant gene alterations for informed cancer management. With a carefully curated set of genes, OncoCore simplifies cancer genomic profiling to improve patient care.

What sets OncoCore apart as the go-to choice for clinicians seeking to improve patient outcomes? Let’s explore its key features:

OncoCore’s Focused Approach

When selecting a gene panel, it’s essential that the results provide the required information for accurate diagnosis and treatment guidance. But does a larger gene panel always guarantee better results? Not necessarily. In fact, research indicates that smaller, optimized gene panels can be just as effective as larger ones in identifying clinically actionable mutations. Having more genetic information in a larger panel does not always translate to clinically significant insights.

OncoCore provides clinically useful results by focusing on 32 key cancer-related genes. The panel covers significant genetic variants for a range of solid tumors including non-small cell lung cancer, melanoma, bile duct cancer, gastrointestinal stromal tumors, colorectal cancer, bladder cancer, and thyroid cancer. Employing targeted amplicon sequencing technology, OncoCore analyzes both DNA and RNA, enabling the comprehensive detection of genetic alterations such as single nucleotide variants, insertions and deletions, gene fusions, and microsatellite instability. This focused but thorough approach ensures the identification of significant gene changes relevant to treatment options, enhancing diagnostic yield and clinical utility.

Rapid Precision Oncology with OncoCore

Time is of the essence when it comes to cancer management, but large-scale gene panels can be time-consuming. However, OncoCore can deliver results within just 3 to 4 days. Its impressively short turnaround time is due to its targeted approach and streamlined processes. Focusing on sequencing a minimal number of genes significantly cuts processing time. In addition, OncoCore’s integrated microfluidic system for library preparation enables a fully automated workflow, further accelerating results acquisition. This expedited turnaround time ensures timely access to vital genetic information for clinicians and patients.

OncoCore’s Automated Reports Help Make Sense of Genetic Data

Interpreting results from gene panels can be daunting, but OncoCore simplifies this process with automated reports that present findings in a clear format. These reports highlight mutations linked to FDA-approved treatments and clinical trial options, empowering clinicians to make well-informed treatment decisions backed by robust genetic insights.

Jump into Action with OncoCore

Having explored the key features that make the OncoCore panel unique, let's review how it can enhance clinical workflows:

· Detect Significant Variants: The OncoCore panel focuses exclusively on clinically significant genetic variants within a patient's tumor, ensuring that only relevant information is provided for understanding the cancer's genetic profile.

· Associated Allele Frequencies and Read Counts: OncoCore’s automatically generated reports include these measures to determine the prevalence of each mutation within the tumor. Higher allele frequencies may indicate dominant mutations driving cancer progression, guiding the selection of the most impactful therapeutic targets.

· Selected Targeted Therapies: OncoCore’s reports link each genetic variant to relevant therapies, supported by evidence tiers that indicate the robustness of clinical data, ensuring treatment decisions are based on the best available evidence.

· Highlight Relevant Clinical Trials: OncoCore’s reports pinpoint ongoing clinical trials suitable for patients based on their specific genetic mutations, expanding potential treatment options.

· Facilitate Collaboration: Share OncoCore’s clear and thorough reports with a multidisciplinary team of clinicians, including surgeons, radiologists, and pathologists, to foster a collaborative approach to treatment planning and ensure all team members are properly informed about the underlying genetics of the cancer.

Integrating OncoCore into clinical practice can provide oncologists with personalized, data-driven treatment plans, improving patient outcomes through precise and timely interventions.

The OncoCore Advantage

When looking for the optimal gene panel for solid tumor cancers, OncoCore stands out as the smart choice. Its insights empower oncologists to make informed treatment decisions swiftly and effectively, leading to better patient outcomes.

Contact us today to discover how OncoCore can make precision oncology a reality!